Pembrolizumab as neoadjuvant & adjuvant therapy improves pCR in early TNBC
03 Oct 2019
byChristina Lau
Pembrolizumab, used in both neoadjuvant and adjuvant settings, significantly improves pathological complete response (pCR) in patients with early triple-negative breast cancer (TNBC), according to late-breaking results of the phase III KEYNOTE-522 trial presented at the European Society for Medical Oncology (ESMO) Congress 2019.